{"id":"tg103","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TG103 is an investigational small-molecule tyrosine kinase inhibitor in Phase 3 development by CSPC Baike. While the precise molecular targets have not been widely disclosed in public literature, it is being evaluated for potential anti-cancer activity. The drug is under clinical development but detailed mechanistic and efficacy data remain limited in the public domain.","oneSentence":"TG103 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:38:10.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05997576","phase":"PHASE3","title":"A Study of TG103 Injection in Non-diabetic Overweight or Obesity","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2023-11-22","conditions":"Overweight or Obesity","enrollment":675},{"nctId":"NCT06258148","phase":"PHASE3","title":"A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2024-03-15","conditions":"Type 2 Diabetes Mellitus","enrollment":465},{"nctId":"NCT06235086","phase":"PHASE3","title":"A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2024-04-08","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT06226090","phase":"PHASE2","title":"A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2024-02-21","conditions":"Obesity, Overweight","enrollment":314},{"nctId":"NCT04855292","phase":"PHASE1","title":"A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2021-07-01","conditions":"Diabetes","enrollment":48},{"nctId":"NCT05348122","phase":"PHASE2","title":"A Study of TG103 Injection in Type 2 Diabetes Subjects","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2022-06-15","conditions":"Type 2 Diabetes Mellitus","enrollment":240},{"nctId":"NCT05299697","phase":"PHASE2","title":"A Study of TG103 Injection in Overweight or Obesity","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2022-05-20","conditions":"Overweight or Obesity","enrollment":195},{"nctId":"NCT04839744","phase":"PHASE1","title":"A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects","status":"COMPLETED","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2021-05-18","conditions":"Healthy Male Subjects","enrollment":24},{"nctId":"NCT05063253","phase":"PHASE2","title":"A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2021-10","conditions":"Type 2 Diabetes Mellitus","enrollment":208},{"nctId":"NCT04790006","phase":"PHASE1","title":"A Study of TG103 in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-04","conditions":"Type 2 Diabetes","enrollment":54},{"nctId":"NCT03990090","phase":"PHASE1","title":"A Study of TG103 in Chinese Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-07-29","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Administered SC"],"phase":"phase_3","status":"active","brandName":"TG103","genericName":"TG103","companyName":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","companyId":"cspc-baike-shandong-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}